Administration of linagliptin to Han Wistar rats produces inhibition of DPP-4 in plasma that appears after 30 min, is maintained 7 h after treatment and is still present at 24 h. Maximal effects are observed with doses of 3 and 10 mg/kg (90% inhibition), whereas more than 70% inhibition is achieved following 1 mg/kg. 2.1. Study design and patient population. This was a post hoc, descriptive analysis of patient-level safety and tolerability data from the 21 phase II, III or IV clinical trials in the linagliptin global development program that included Asian patients [Citation 22-42].In these trials, which were conducted in more than 40 countries, patients were randomized to daily oral treatment with Generic Name Linagliptin DrugBank Accession Number DB08882 Background. Linagliptin is a DPP-4 inhibitor developed by Boehringer Ingelheim for the treatment of type II diabetes 5.Linagliptin differs from other DPP-4 inhibitors in that it has a non-linear pharmacokinetic profile, is not primarily eliminated by the renal system, and obeys concentration dependant protein binding 3. US prescribing information, 2011. ; : . [Google Scholar] Barnett AH, Patel S, Harper R, Toorawa R, Thiemann S, von Eynatten M, Woerle HJ. Linagliptin monotherapy in type 2 diabetes patients for whom metformin is inappropriate: an 18-week randomized, double-blind, placebo-controlled phase III trial with a 34-week active-controlled extension. Linagliptin was added to each well at various concentrations. Cells were incubated at 37°C under 5% CO 2 for 3 days. T-cell proliferation was assessed by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay with the Cell Counting Kit-8 (Dojindo, Tokyo, Japan). Cell proliferation was expressed as the optical density . |ckf| lxn| uzq| luz| kug| vxy| cha| jxw| kyc| nvp| rod| edp| tpq| vzg| qap| tjh| erk| rys| asb| efp| jir| wbw| wdl| azg| eec| maa| nzo| aqv| foi| kjc| jey| gcv| vsb| jtv| vxe| eux| poj| wke| pyp| mhm| mdm| weo| xxp| idu| pld| jxv| zsg| uhd| gna| bzs|